FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:2515-2516 December 11, 2008 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Prostate-cancer screening with the prostate-specific antigen (PSA) test remains one of the most controversial issues in modern medicine. The U.S. Preventive Services Task Force (USPSTF), an independent group of experts supported by the Agency for Healthcare Research and Quality under a mandate from Congress, recently revised its recommendations regarding prostate-cancer screening. The USPSTF concluded that "the current evidence is insufficient to assess the balance of benefits and harms of prostate cancer screening in men younger than age 75 years," but it now "recommends against screening for prostate cancer in men age 75 years or older."¹ In its 2002 statement, the . . . [Full Text of this Article]

Source Information

Dr. Barry is the medical director of the John D. Stoeckle Center for Primary Care Innovation at Massachusetts General Hospital and a professor of medicine at Harvard Medical School — both in Boston.

This article has been cited by other articles:

• Montie, J. E., Carducci, M. A., Kuban, D. A. (2009). Perspectives on the Management of Localized Prostate Cancer: Focus on Radiotherapy. Am Soc Clin Oncol Ed Book 2009: 270-274 [Abstract] [Full Text]